Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. (Q45494455)

14 December 2017

title

Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. (English)

1 reference

14 December 2017

1 reference

1 reference

11

Masashi Mizokami

1 reference

14 December 2017

3

Yasuhito Tanaka

1 reference

14 December 2017

8

Fuminaka Sugauchi

1 reference

14 December 2017

9

Tomoyoshi Ohno

1 reference

14 December 2017

2

Etsuro Orito

1 reference

14 December 2017

10

Ryuzo Ueda

1 reference

Cintia Mayumi Sakurai Kimura

14 December 2017

series ordinal

6

object named as

Mayumi Sakurai

1 reference

14 December 2017

4

Noboru Hirashima

1 reference

14 December 2017

5

Kenji Sakakibara

1 reference

14 December 2017

Izumi Hasegawa

1

1 reference

14 December 2017

Seiji Suzuki

series ordinal

7

1 reference

14 December 2017

publication date

1 April 2005

1 reference

14 December 2017

1 reference

14 December 2017

volume

25

1 reference

14 December 2017

issue

2

1 reference

14 December 2017

page(s)

247-253

1 reference

Hepatitis B virus transgenic mice: insights into the virus and the disease

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Occult hepatitis B virus infection and liver disease: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

The impact of previous HBV infection on the course of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

State of HBV DNA in HBsAg-negative, anti-HCV-positive hepatocellular carcinoma: existence of HBV DNA possibly as nonintegrated form with analysis by Alu-HBV DNA PCR and conventional HBV PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.1096.X

10.1111/J.1478-3231.2005.1096.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference